clinical trial · NCT04438304
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Neuroendocrine Tumors64Cu-SARTATE
brief summary
The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.
started
Mar 2, 2021
primary completion
Nov 26, 2024
completion
Nov 26, 2024
last updated
Feb 12, 2025
detailed description
Up to 63 participants will be recruited in this study and who are confirmed or suspected to have NETs based on biochemical evidence or that of conventional anatomical or molecular imaging.
official title
Positron Emission Tomography Imaging of Participants With Known or Suspected Neuroendocrine Tumours Using 64Cu SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol